Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) major shareholder Pharma Technologies Ltd Dexcel bought 4,000,000 shares of the stock in a transaction dated Thursday, November 10th. The shares were bought at an average cost of $5.00 per share, with a total value of $20,000,000.00. Following the completion of the acquisition, the insider now directly owns 102,849,443 shares of the company’s stock, valued at approximately $514,247,215. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Roivant Sciences Stock Performance
ROIV opened at $5.29 on Tuesday. The company has a market capitalization of $3.72 billion, a price-to-earnings ratio of -3.31 and a beta of 1.89. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.20 and a quick ratio of 6.20. Roivant Sciences Ltd. has a 1-year low of $2.52 and a 1-year high of $16.76. The business has a 50 day moving average price of $4.20 and a two-hundred day moving average price of $4.08.
Roivant Sciences (NASDAQ:ROIV – Get Rating) last announced its quarterly earnings data on Monday, August 15th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.18). Roivant Sciences had a negative net margin of 2,110.83% and a negative return on equity of 68.61%. The company had revenue of $4.32 million for the quarter, compared to analyst estimates of $6.45 million. Research analysts predict that Roivant Sciences Ltd. will post -1.72 EPS for the current fiscal year.
Institutional Investors Weigh In On Roivant Sciences
Analysts Set New Price Targets
Several equities analysts have recently commented on ROIV shares. JPMorgan Chase & Co. started coverage on Roivant Sciences in a report on Thursday, October 27th. They set an “overweight” rating and a $7.00 target price for the company. Citigroup boosted their price objective on Roivant Sciences from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $10.83.
Roivant Sciences Company Profile
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
- Get a free copy of the StockNews.com research report on Roivant Sciences (ROIV)
- Wayfair Still Has Its Fair Share of Issues
- Why did NIO take a $581.11 million loss last quarter?
- Take Two Interactive Software Stock is Taking One Step Back
- This Mid-Cap Tech Stock Embodies Diversified Growth
- Is It Time To Take A Ride With Joby Aviation’s EV Innovations?
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.